



Company Summary

Orasi Medical provides neurological biomarkers based on electrical activity of the brain. Our flagship product, **Orasi Index™** accelerates neurological and psychiatric drug development, reduces costs and improves outcomes, providing pharmaceutical companies invaluable insight by:

- Confirming the drug reaches the brain
- Identifying the most effective dose
- Selecting the best patients, and
- Measuring drug effect earlier and more accurately.

Orasi has the largest database of magnetoencephalography (MEG) brain scans and biomarkers and clinical data for an expanding range of drug signatures and disease patterns.

Orasi's biomarkers are being developed to help diagnosis and assess progression of CNS diseases such as Alzheimers disease, multiple sclerosis, tinnitus, schizophrenia, and depression as well as others. These additional magnetoencephalography (MEG) and electroencephalography (EEG) biomarkers will further improve drug development by supporting later stage clinical trials.

Orasi has the largest database of MEG brain scans, MEG biomarkers, and supporting clinical data for an expanding range of drug signatures and disease patterns.



Electrophysiology While fully supporting traditional EEG technology, the Orasi Index excels when applied to MEG. More advanced than EEG, MEG non-invasively measures magnetic fields generated by neuronal activity providing an accurate and objective evaluation of brain function.



Analytical Engine The Orasi Index assesses both standard relative spectral power and functional connectivity using Orasi's proprietary Synchronous Neural Interaction (SNI) Test™ to fully characterize patient response to CNS drugs. With the largest commercial database of MEG scans and clinical data, Orasi Index provides an expanding library of functional signatures specific for an array of CNS drugs and diseases.



OrasiView Customers can access Orasi Index and their clinical trial results online using OrasiView. OrasiView is a web-based analysis and reporting tool that enables researchers to evaluate pharmacodynamics, drug mechanism, dose selection, and ongoing treatment effect, thereby supporting the critical decisions needed for successful CNS drug development.

Product Features

1. Pharmacodynamics

Assessing the pharmacodynamics of CNS drugs presents a unique development hurdle. Understanding brain penetration, PK/PD relationships, and drug mechanism are critical for success in early development. Current tools for measuring brain-drug interactions provide limited and sometimes inaccurate information.

Orasi Index™ can help improve drug success by confirming where and when a drug is altering brain function. Orasi Index™ improves drug success by confirming where and when drug alters brain function.

2. Accurate selection of drug dose

Using Orasi Index™, drug developers can review magnetoencephalography (MEG) or electroencephalography (EEG) results to assess response to drug treatment and confidently select optimal dose. Our technology can reveal electrophysiology features that support critical decision-making.

Orasi Index™ provides robust drug-effect relationship information.




Fig 1 Pharmacodynamic profile of three neuroactive drugs as measured by the Orasi Index




Fig 2 Dose response of OR914 as measured by the Orasi Index

3. Invaluable insight into drug mechanisms

The Orasi Index includes the world's largest database of MEG results and associated clinical information. This allows drug developers to visualize and compare the effect of experimental compounds with known drug and disease signatures.

Orasi Index™ improves drug success by comparing a test compound with known drug signatures.




Fig 3 Comparison of the unique mechanism of OR914 to the signatures of three common neuroactive drugs with Orasi Index

4. Tools for selecting the right patients

Drug failures often are caused by inadequate or poor study population selection. Defining and then recruiting the right study group requires objective tools to characterize disease states and stages.

Orasi Index™ enhances CNS trial success by improving patient selection.




Fig 4 Measuring Alzheimer's disease severity (n=317) by the Orasi Index



Contact

Please contact for more information about Orasi Medical products and services

Sarah Haecker, PhD
VP, Pharmaceutical Business Development
Orasi Medical, Inc.

sarah.haecker@orasimedical.com
800.383.9547
www.orasimedical.com